KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMY) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $4.0 billion.

  • Bristol Myers Squibb's Accumulated Depreciation & Amortization fell 5821.88% to $4.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 billion, marking a year-over-year decrease of 5821.88%. This contributed to the annual value of $4.0 billion for FY2025, which is 5821.88% down from last year.
  • Per Bristol Myers Squibb's latest filing, its Accumulated Depreciation & Amortization stood at $4.0 billion for Q4 2025, which was down 5821.88% from $3.0 billion recorded in Q3 2025.
  • Bristol Myers Squibb's Accumulated Depreciation & Amortization's 5-year high stood at $10.7 billion during Q4 2021, with a 5-year trough of $1.0 billion in Q1 2025.
  • Its 5-year average for Accumulated Depreciation & Amortization is $5.6 billion, with a median of $5.1 billion in 2022.
  • In the last 5 years, Bristol Myers Squibb's Accumulated Depreciation & Amortization skyrocketed by 771.09% in 2021 and then plummeted by 6069.95% in 2025.
  • Over the past 5 years, Bristol Myers Squibb's Accumulated Depreciation & Amortization (Quarter) stood at $10.7 billion in 2021, then fell by 3.84% to $10.3 billion in 2022, then dropped by 5.02% to $9.8 billion in 2023, then decreased by 1.64% to $9.6 billion in 2024, then crashed by 58.22% to $4.0 billion in 2025.
  • Its Accumulated Depreciation & Amortization was $4.0 billion in Q4 2025, compared to $3.0 billion in Q3 2025 and $2.0 billion in Q2 2025.